does bpc 157 reduce inflammation 🧬 BPC-157 Peptide Therapy BPC-157 Explained: Benefits, Safety &

Stage IV

Ideal Candidate Profiles Adults with confirmed GH deficiency by stimulation testing Patients experiencing age-related GH decline Individuals with mild to moderate metabolic syndrome Contraindications and Precautions Active cancer or history of pituitary tumors Untreated thyroid disorders Pregnancy or breastfeeding Severe kidney or liver impairment Disclose all medical history and medications before starting sermorelin therapy

The 12mg cohort achieved the highest mean body weight reduction at -24.2% exceeding all published results for semaglutide (approximately -16% in the STEP trials) and tirzepatide (approximately -22.5% in SURMOUNT-1) at their respective maximum doses

doi:10.3390/biomedicines9060609 Hsieh MJ, Lee CH, Chueh HY, et al